866-997-4948(US-Canada Toll Free)

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Cancer

No. of Pages : 322 Pages


Global Markets Directs, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2015, provides an overview of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 6
List of Figures 8

Introduction 9
Global Markets Direct Report Coverage 9
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview 11
Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis 12
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 18
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 22
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 27
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 28
A. Menarini Industrie Farmaceutiche Riunite Srl 28
Adamis Pharmaceuticals Corporation 29
Aeterna Zentaris Inc. 30
Alethia Biotherapeutics Inc. 31
Amgen Inc. 32
AnGes MG, Inc. 33
Aphios Corporation 34
Armour Therapeutics Inc. 35
Arno Therapeutics, Inc. 36
Astellas Pharma Inc. 37
Astex Pharmaceuticals, Inc. 38
AstraZeneca PLC 39
Ausio Pharmaceuticals, LLC 40
Bavarian Nordic A/S 41
Bayer AG 42
Beta Pharma, Inc. 43
Bio-Cancer Treatment International Limited 44
Biscayne Pharmaceuticals, Inc. 45
Boehringer Ingelheim GmbH 46
Celldex Therapeutics, Inc. 47
Corcept Therapeutics Incorporated 48
CureTech Ltd. 49
CytoVac A/S 50
DexTech Medical AB 51
Enceladus Pharmaceuticals BV 52
Endo Pharmaceuticals Inc. 53
EndoCeutics, Inc. 54
Endocyte, Inc. 55
Errant Gene Therapeutics, LLC 56
Fujifilm Corporation 57
Genentech, Inc. 58
Glactone Pharma AB 59
GlaxoSmithKline plc 60
GTx, Inc. 61
Harbor Therapeutics, Inc. 62
Hybrigenics S.A. 63
Incuron, LLC 64
Io Therapeutics, Inc. 65
Isis Pharmaceuticals, Inc. 66
Johnson & Johnson 67
Kinex Pharmaceuticals, LLC 68
Mediolanum farmaceutici S.p.A. 69
Medivation, Inc. 70
Merck KGaA 71
NewLink Genetics Corporation 72
Novartis AG 73
Oncogenex Pharmaceuticals, Inc. 74
Orion Oyj 75
Orphagen Pharmaceuticals, Inc. 76
Oxford BioMedica plc 77
Panacela Labs, Inc. 78
Takeda Oncology 79
Tokai Pharmaceuticals, Inc. 80
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 81
Assessment by Monotherapy Products 81
Assessment by Target 82
Assessment by Mechanism of Action 86
Assessment by Route of Administration 89
Assessment by Molecule Type 91
Drug Profiles 93
AB-3A4 - Drug Profile 93
afatinib - Drug Profile 94
AKAGU-52 - Drug Profile 98
Alecsat - Drug Profile 99
alisertib - Drug Profile 101
AM-0010 - Drug Profile 105
AMPI-109 - Drug Profile 106
apatorsen - Drug Profile 107
APH-0701 - Drug Profile 109
AT-001 - Drug Profile 110
AUS-131 - Drug Profile 111
AZD-3965 - Drug Profile 113
AZD-8186 - Drug Profile 115
BAY-1024767 - Drug Profile 116
BCT-100 - Drug Profile 117
BIS-1602 - Drug Profile 119
BPI-5143 - Drug Profile 120
buparlisib hydrochloride - Drug Profile 121
CG-1521 - Drug Profile 125
CIM-1 - Drug Profile 126
Dendritic Cell Therapy to Target Mucin 1 for Prostatic Adenocarcinoma - Drug Profile 127
dexamethasone acetate - Drug Profile 128
EC-1169 - Drug Profile 129
EM-5854 - Drug Profile 130
EN-3356 - Drug Profile 131
enzalutamide - Drug Profile 133
EPI-001 - Drug Profile 136
galeterone - Drug Profile 137
GEN-0101 - Drug Profile 139
GPA-500 - Drug Profile 141
GPA-512 - Drug Profile 142
GPB-600 - Drug Profile 143
GSK-2849330 - Drug Profile 144
GTx-758 - Drug Profile 145
GX-301 - Drug Profile 147
HE-3235 - Drug Profile 148
HyperAcute Vaccine for Prostate Cancer - Drug Profile 150
inecalcitol - Drug Profile 151
ipatasertib - Drug Profile 153
IRX-4204 - Drug Profile 155
ISIS-EIF4ERx - Drug Profile 157
ITK-1 - Drug Profile 159
JNJ-56021927 - Drug Profile 161
KRM-20 - Drug Profile 163
KX-01 - Drug Profile 164
LFA-102 - Drug Profile 166
mepacrine - Drug Profile 168
MIA-602 - Drug Profile 170
mifepristone - Drug Profile 171
MSB-0010718C - Drug Profile 174
MVA-BN-PRO - Drug Profile 175
MVI-118 - Drug Profile 176
ODM-201 - Drug Profile 177
onalespib - Drug Profile 179
onapristone ER - Drug Profile 182
Oncolytic Virus for Oncology - Drug Profile 184
ozarelix - Drug Profile 185
pasireotide LAR - Drug Profile 187
pasotuxizumab - Drug Profile 189
Peptide for Androgen-Independent Prostate Cancer - Drug Profile 191
pidilizumab - Drug Profile 192
radium Ra 223 dichloride - Drug Profile 194
ribociclib - Drug Profile 197
rilotumumab - Drug Profile 200
sabarubicin - Drug Profile 202
Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer - Drug Profile 204
Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer - Drug Profile 205
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 206
Small Molecules to Inhibit AKR1C3 for Oncology - Drug Profile 207
solitomab - Drug Profile 208
Somadex - Drug Profile 210
SR-16388 - Drug Profile 211
TeloB-VAX - Drug Profile 213
TroVax - Drug Profile 214
vandetanib - Drug Profile 217
varlilumab - Drug Profile 223
VT-464 - Drug Profile 225
zoptarelin doxorubicin - Drug Profile 226
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 228
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 297
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 303
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 305
Featured News & Press Releases 305

Appendix 315
Methodology 315
Coverage 315
Secondary Research 315
Primary Research 315
Expert Panel Validation 315
Contact Us 315
Disclaimer 316

List of Table


Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2015 17
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Late Stage Development, H1 2015 25
Comparative Analysis by Clinical Stage Development, H1 2015 26
Comparative Analysis by Early Stage Development, H1 2015 27
Products under Development by Companies, H1 2015 28
Products under Development by Companies, H1 2015 (Contd..1) 29
Products under Development by Companies, H1 2015 (Contd..2) 30
Products under Development by Companies, H1 2015 (Contd..3) 31
Products under Development by Companies, H1 2015 (Contd..4) 32
Products under Investigation by Universities/Institutes, H1 2015 33
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 34
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 35
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015 36
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015 37
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Amgen Inc., H1 2015 38
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AnGes MG, Inc., H1 2015 39
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Aphios Corporation, H1 2015 40
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Armour Therapeutics Inc., H1 2015 41
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H1 2015 42
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2015 43
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 44
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H1 2015 45
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ausio Pharmaceuticals, LLC, H1 2015 46
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2015 47
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bayer AG, H1 2015 48
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Beta Pharma, Inc., H1 2015 49
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2015 50
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 51
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 52
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 53
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 54
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureTech Ltd., H1 2015 55
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CytoVac A/S, H1 2015 56
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by DexTech Medical AB, H1 2015 57
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H1 2015 58
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H1 2015 59
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by EndoCeutics, Inc., H1 2015 60
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Endocyte, Inc., H1 2015 61
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H1 2015 62
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Fujifilm Corporation, H1 2015 63
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H1 2015 64
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Glactone Pharma AB, H1 2015 65
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 66
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H1 2015 67
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Harbor Therapeutics, Inc., H1 2015 68
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Hybrigenics S.A., H1 2015 69
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Incuron, LLC, H1 2015 70
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Io Therapeutics, Inc., H1 2015 71
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 72
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H1 2015 73
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 74
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Mediolanum farmaceutici S.p.A., H1 2015 75
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H1 2015 76
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H1 2015 77
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H1 2015 78
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H1 2015 79
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 80
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orion Oyj, H1 2015 81
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 82
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oxford BioMedica plc, H1 2015 83
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Panacela Labs, Inc., H1 2015 84
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Oncology, H1 2015 85
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H1 2015 86
Assessment by Monotherapy Products, H1 2015 87
Number of Products by Stage and Target, H1 2015 89
Number of Products by Stage and Mechanism of Action, H1 2015 93
Number of Products by Stage and Route of Administration, H1 2015 96
Number of Products by Stage and Molecule Type, H1 2015 98
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H1 2015 234
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H1 2015 303
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..1), H1 2015 304
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..2), H1 2015 305
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..3), H1 2015 306
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..4), H1 2015 307
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects (Contd..5), H1 2015 308
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H1 2015 309
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products (Contd..1), H1 2015 310

List of Chart


Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H1 2015 17
Number of Products under Development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 19
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 26
Comparative Analysis by Early Stage Products, H1 2015 27
Assessment by Monotherapy Products, H1 2015 87
Number of Products by Top 10 Targets, H1 2015 88
Number of Products by Stage and Top 10 Targets, H1 2015 88
Number of Products by Top 10 Mechanism of Actions, H1 2015 92
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 92
Number of Products by Top 10 Routes of Administration, H1 2015 95
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 95
Number of Products by Top 10 Molecule Types, H1 2015 97
Number of Products by Stage and Top 10 Molecule Types, H1 2015 97

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *